Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewApoptosis in pancreatic β-islet cells in Type 2 diabetesSodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidenceEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsPractical combination therapy based on pathophysiology of type 2 diabetesThe management of type 2 diabetic patients with hypoglycaemic agentsWhy Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansRationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesLoss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Acute anti-hyperglycaemic effects of an unripe apple preparation containing phlorizin in healthy volunteers: a preliminary study.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe molecular mechanism of ion-dependent gating in secondary transporters.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsSodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the potDapagliflozin lowers plasma glucose concentration and improves β-cell functionEfficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 DiabetesCentral obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Novel Agents for the Treatment of Type 2 Diabetes.Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic MiceCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusThe potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusA novel SGLT is expressed in the human kidney.Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialSGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
P2860
Q24563917-A90F6992-4208-4FCF-B6D0-5B8802729AB5Q26747141-4BCC6C1A-9354-4104-82D6-E7AC2EE6A7A4Q26752703-1E8ADE24-B5ED-48ED-8D63-E2A61E01CDBDQ26782225-909CEE31-0C7A-4245-A407-196747DA968EQ26824616-1F26FCB3-AC00-4FFC-9FF3-4D58C660CF0CQ28076530-3DE01EB4-76C2-4DAB-AD0F-8D7C82ED3768Q30417363-192CBD96-C3F2-41D3-8D18-0995B6DCBB1DQ33354192-CEA88EA3-C9C3-4F7D-99A0-A8A0B5C1CFBBQ33356608-901D9C9E-AC0C-46E5-BB50-F86DDE917C4FQ33556240-71596171-BD75-4C71-81FB-948DEFEDB451Q33665173-9300EAEA-EF82-4898-9572-65B2CAD88F92Q33696974-674991FE-8F6F-4B09-982E-E01D60A47D8EQ33701505-B25921DE-7BDD-4E49-831D-CE555EF846DDQ33812170-F82EA070-3425-4E63-A290-FBA5ABB5235FQ33837017-713EBAE4-E66F-4AC4-BCF3-4FBBEBECEE1BQ34105064-CD0186AC-5DC5-49F6-BDCC-1A57C88C2D2CQ34161881-7D34748B-8ACE-48F3-806C-903D54BC504FQ34198692-3D024AE4-9286-42DB-9763-763ABF987551Q34317153-CC868594-084A-455C-BAC8-80E89923D456Q34397646-DBF08B61-79DB-400B-B8FD-BFF604981BFDQ34424092-9BD4F8D5-8052-4853-80EB-73FDEBBC2B81Q34502358-5A1EE610-6895-42D1-B27C-DDF35E52A71BQ35034126-75BB6504-0CB5-48CF-81D5-8785576F3EA8Q35068181-82CE70EE-DB1F-4516-894F-8529B0CFDFB2Q35192356-911E24E9-ECAB-4B39-BFA5-D252F5382E17Q35578244-5784DD86-BDCE-4AF9-914A-EB75BBC91477Q35796638-F1B0FA70-8EB2-42DB-AD16-B24AC531F297Q35829203-74C7B91F-3410-4143-9D7A-AA9A51A7CF42Q35910421-526D809F-DE34-46D7-A97F-096AF950C7D5Q36057947-D403A449-A6F7-4059-906E-A101D1C6976CQ36303346-90F54F79-92AA-43A5-8993-9FD16B2D3F8FQ36345951-9E972CA9-5BAD-4DD9-90E7-B9CF051B6469Q36592820-89FBEC64-F89C-4FB0-B9DD-7D2185FC6461Q36706015-78D293B6-121A-4BCB-8EAA-1A05FE045470Q36716030-7957103F-7D02-4D44-BE49-FE8E2384934AQ36782790-9026D107-0E0F-412D-AD79-818ABCFD035FQ36820255-7CDA29B2-8386-4879-A147-331A98AA23DBQ36820604-7A268E55-92EC-486C-9E8C-E11D7AD2C132Q36960633-226BB61E-FA88-46BE-A4C3-10DFA9485E40Q36997767-BC598DF7-3699-4A79-BC76-F1E3D65530F3
P2860
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of sodium-glucose cotrans ...... treatment of type 2 diabetes.
@en
Role of sodium-glucose cotransporter 2
@nl
type
label
Role of sodium-glucose cotrans ...... treatment of type 2 diabetes.
@en
Role of sodium-glucose cotransporter 2
@nl
prefLabel
Role of sodium-glucose cotrans ...... treatment of type 2 diabetes.
@en
Role of sodium-glucose cotransporter 2
@nl
P921
P356
P1433
P1476
Role of sodium-glucose cotrans ...... e treatment of type 2 diabetes
@en
P2093
Muhammad A Abdul-Ghani
Ralph A Defronzo
P304
P356
10.1210/ER.2010-0029
P50
P577
2011-05-23T00:00:00Z